Clearmind Medicine Inc. — Form 6-K Summary
Filing date: February 9, 2024. Reporting period: February 2024. The filing addresses the Company’s compliance with Nasdaq’s shareholder-equity requirement.
Business Context and Financial Position
Clearmind Medicine Inc. is a foreign private issuer filing annual reports on Form 20-F. Its Annual Report reported shareholders’ equity below Nasdaq’s $2.5 million continued-listing requirement as of October 31, 2023.
- After giving effect to subsequent financing transactions, the Company estimates its as-adjusted shareholders’ equity at approximately $7 million.
- The filing does not provide current revenue, net income, operating cash flow, cash balance, margins, or debt figures.
Material Changes Since October 31, 2023
- Warrant exercises: 1,062,188 warrants issued in the March 2023 and September 2023 public offerings were exercised for aggregate gross proceeds of approximately $3.476 million.
- January Offering: On January 11, 2024, the Company issued and sold 1,500,000 common shares and/or pre-funded warrants, together with associated common warrants, at a public offering price of $1.60 per common share and associated warrant.
- The Company believes these transactions restored compliance with Nasdaq’s shareholder-equity requirement.
Outlook, Risks, and Contingencies
Nasdaq will continue monitoring the Company’s compliance. If the Company does not demonstrate compliance in its next interim report, it may be subject to delisting. The approximately $7 million shareholder-equity figure is an as-adjusted estimate and does not represent a reported period-end balance.
Investor Verification Items
- Verify the final accounting treatment and reported impact of the warrant exercises and January Offering on shareholders’ equity.
- Review the next interim report for evidence of continued compliance with Nasdaq’s $2.5 million shareholder-equity requirement.
- Assess dilution from the shares, pre-funded warrants, common warrants, and exercised warrants.
- Confirm current cash, operating cash burn, debt, and financing requirements, which are not provided in this filing.